8-K: Know Labs Secures $1.655 Million in Registered Direct Offering

Know Labs, Inc. has successfully completed a registered direct offering, raising $1.655 million through the sale of units consisting of common stock and warrants.

Summary

• Know Labs, Inc. has finalized a registered direct offering, generating gross proceeds of $1.655 million.
• The offering involved the sale of 6,365,385 units, each priced at $0.26.
• Each unit included one share of common stock and one warrant to purchase an additional share at $0.26.
• The company intends to allocate the net proceeds towards product development, clinical studies, general expenses, intellectual property, and working capital.
• Boustead Securities, LLC and The Benchmark Company, LLC acted as advisors for the offering and received a 5% cash fee and warrants to purchase 636,538 shares.
• The offering was made under an existing shelf registration statement and a related prospectus supplement.

Sentiment

Score: 7

Explanation: The document indicates a successful capital raise, which is generally positive. However, the low offering price and the fees paid to advisors temper the overall sentiment. The company's future success is still dependent on product development and regulatory approvals.

Positives

• The company successfully raised capital to fund its operations and development plans.
• The offering was completed quickly, closing on the same day as the agreement.
• The company has secured funding for key areas such as product development and clinical studies.

Negatives

• The company incurred a 5% cash fee to the advisors, reducing the net proceeds.
• The offering price of $0.26 per unit may be considered low, potentially diluting existing shareholders.

Risks

• The company's management has broad discretion in using the net proceeds, which may not align with investor expectations.
• The company's future success depends on the successful development and commercialization of its products, which is subject to regulatory approvals and market acceptance.
• The company is subject to risks associated with product development, clinical studies, and intellectual property protection.

Future Outlook

The company intends to use the net proceeds from the offering primarily to continue product development of the KnowU glucose monitoring products, including sales and marketing efforts and clinical studies, intellectual property development, and for operating expenses and working capital purposes. The company also plans to invest the net proceeds in short-term, interest-bearing, investment-grade securities pending their final application.

Management Comments

• The company's management will have broad discretion in the way that we use the net proceeds of this offering and we may use the proceeds for purposes that are not contemplated at the time of the Offering.

Industry Context

This capital raise is typical for a development-stage medical technology company seeking to fund product development and clinical trials. The company's focus on non-invasive glucose monitoring aligns with a growing trend in the healthcare industry towards more convenient and patient-friendly diagnostic solutions.

Comparison to Industry Standards

• The use of a registered direct offering is a common method for raising capital for companies in the biotechnology and medical device sectors.
• The offering price of $0.26 per unit is relatively low, which may be reflective of the company's current stage of development and market capitalization.
• The 5% cash fee to advisors is within the typical range for such transactions.
• Comparable companies in the medical device space often utilize similar funding strategies to advance their technologies through clinical trials and regulatory approvals.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from the company's increased financial stability and growth prospects.
• Customers may benefit from the development of new and innovative medical technology.
• Suppliers and creditors may benefit from the company's improved financial position.

Next Steps

• The company will use the net proceeds for product development, clinical studies, and working capital.
• The company will file a final prospectus supplement with the SEC.
• The company will continue to develop its non-invasive glucose monitoring technology.

Key Dates

Keywords

registered direct offering, common stock, warrants, capital raise, product development, clinical studies, non-invasive glucose monitor, medical technology, spectroscopy